EMG
AERI

Ellington Management Group’s Aerie Pharmaceuticals AERI Stock Holding History

Ellington Management Group’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,300
Closed -$223K – 741
2018
Q2 		$223K Buy
+3,300
New +$185K 0.02% 381
2016
Q4 		– Sell
-20,100
Closed -$759K – 867
2016
Q3 		$759K Buy
+20,100
New +$443K 0.21% 138
2015
Q3 		– Sell
-12,400
Closed -$219K – 946
2015
Q2 		$219K Buy
+12,400
New +$227K 0.05% 561

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ellington Management Group's AERI Position: Q3 2018 in Review

Ellington Management Group sold out of Aerie Pharmaceuticals (AERI) in Q3 2018, closing a stake of 3,300 shares — an estimated $223K sold.

Ellington Management Group first reported a position in AERI in Q2 2015 and held it in 3 quarters. The position peaked at $759K in Q3 2016. 176 funds tracked by Wall St. Rank hold AERI as of Q3 2018.

  • Ellington Management Group reported no remaining Aerie Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 3,300 Aerie Pharmaceuticals shares in Q3 2018, an estimated $223K.
  • Ellington Management Group first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Ellington Management Group's Aerie Pharmaceuticals position peaked at $759K in Q3 2016.
  • 176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.